Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 138.15 Delayed Data As of Apr 09 |  -4.35 / -3.06%Today’s Change | 110.74 Today|||52-Week Range 178.41 | +6.29% Year-to-Date |
Latest ALNY News | Press Releases
No recent news for Alnylam Pharmaceuticals Inc.
Today’s Trading
| Previous close | 142.50 |
| Today’s open | 142.76 |
| Day’s range | 137.26 - 142.76 |
| Volume | 12,511 |
| Average volume (3 months) | 628,550 |
| Market cap | $16.2B |
Data as of 3:59pm ET, 04/09/2021
Growth & Valuation
| Earnings growth (last year) | +7.96% |
| Earnings growth (this year) | +15.97% |
| Earnings growth (next 5 years) | +55.99% |
| Revenue growth (last year) | +124.28% |
| P/E ratio | NM |
| Price/Sales | 30.32 |
| Price/Book | 15.80 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VTRSViatris Inc | +0.10 | +0.75% |
| INCYIncyte Corp | -0.86 | -1.06% |
| CTLTCatalent Inc | +1.83 | +1.70% |
| ---- |
Data as of 4:00pm ET, 04/09/2021
Financials
| Next reporting date | May 6, 2021 |
| EPS forecast (this quarter) | -$1.73 |
| Annual revenue (last year) | $492.9M |
| Annual profit (last year) | -$858.3M |
| Net profit margin | -174.15% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
